Niall Martin has extensive experience in cancer therapeutics both in small companies and pharma. He is a world leading expert in DNA Damage Response (DDR) and played a key role in the discovery and development of Lynparza™ (olaparib), the first PARP to market and now a multi-billion dollar drug used to treat advanced cancers.

Prior to joining Artios Pharma, Niall was a co-founder and COO at MISSION Therapeutics, he helped establish the DUB inhibitor platform and raise more than £80 million in Series A and B financing. Prior to this, Niall worked as Head of KuDOS Pharmaceuticals (acquired by AstraZeneca) delivering a number of DDR projects into the AstraZeneca oncology pipeline, including ATR and ATM.